If you have started a GLP-1 medication, you have probably seen a viral post claiming the drugs “destroy muscle.” The actual 2026 clinical literature is less dramatic and more useful. Some lean-mass loss happens during any meaningful weight loss, whether the weight comes off through medication, surgery, or diet alone. What the trials show is the proportion. What clinicians now study is the protective strategies that change that proportion.
This is a science-first look at what the STEP and SURMOUNT trials measured, what that tells us about the medication versus the weight loss itself, and the two evidence-based things researchers consistently identify as protective.
Semaglutide is a GLP-1 receptor agonist. The molecule binds the receptor in cells across the brain, gut, and pancreas to slow gastric emptying, reduce appetite signaling, and amplify the natural insulin response to food.
What the STEP and SURMOUNT trials actually showed
Two trials are doing most of the work in the muscle-loss conversation.
The first is STEP 1 (Wilding et al., NEJM 2021), the registrational obesity trial for semaglutide 2.4 mg weekly. Across 1,961 adults followed for 68 weeks, mean weight change was −14.9% with semaglutide compared with −2.4% with placebo. Individual results vary; the trial reports a group average over a specific dose and duration, not a personal forecast. Within STEP 1, a 140-participant subgroup underwent dual-energy X-ray absorptiometry (DXA) to measure body composition. That substudy reported decreases in both total fat mass and total lean mass, with the proportion of lean mass to total body mass actually increasing. Those DXA findings were exploratory and were not corrected for multiplicity, so they are best read as a signal, not a definitive readout.
The second is the SURMOUNT-1 body-composition substudy (Look et al., 2025, derived from the parent trial Jastreboff et al., NEJM 2022). 160 SURMOUNT-1 participants (124 on pooled tirzepatide doses and 36 on placebo) completed DXA at baseline and Week 72. The reported group averages over that 72-week window (individual results vary):
- Body weight: −21.3% with tirzepatide, −5.3% with placebo (individual results vary)
- Fat mass: −33.9% with tirzepatide, −8.2% with placebo (individual results vary)
- Lean mass: −10.9% with tirzepatide, −2.6% with placebo (individual results vary)
The framing the authors highlighted: roughly 75% of the weight lost was fat and roughly 25% was lean mass, and that proportion was similar in both groups. That ratio held across subgroups by sex, age, and weight-loss tertile. Individual results vary, and these figures come from one substudy in one trial. The signal is consistent with what other reviews of weight-loss interventions have reported.
The honest takeaway: significant weight loss produces some loss of lean mass. The drug does not appear to disproportionately attack muscle. The medication is the cause of the weight loss, and the weight loss is the cause of the lean-mass change.
Why older adults need a different conversation
Lean mass matters at every age. It matters more after about 50, because lean mass and grip strength are tied to function (how well someone gets out of a chair, climbs stairs, recovers from illness), and because age-related muscle loss adds to whatever happens during treatment.
The SURMOUNT-1 substudy reported its subgroup analyses by age, and the broad pattern of about 75% fat / 25% lean held. That is reassuring, but a proportion is not the whole story. An older adult who starts at lower lean mass has less to give before strength or function is affected. Federal physical activity guidelines recommend at least 150 minutes of moderate aerobic activity per week and at least two days per week of muscle-strengthening activity for adults, and that is a baseline, not an upper limit. Older adults on GLP-1 therapy are an active research area, and a clinician should be the one calibrating the plan to age, baseline strength, joint health, and medications.
If you are over 60 and considering GLP-1 treatment, the right move is to put lean mass on the agenda from the first visit, not the third.
The two evidence-based protective strategies
Across the clinical reviews of weight-loss treatment, two protective strategies come up again and again. Neither is exotic. Both are general clinical guidance, not a REMEVi-specific claim.
1. Adequate dietary protein. Protein supports the repair of muscle tissue, and protein eaten across meals, rather than concentrated in one meal, appears to support muscle protein synthesis more reliably. Clinical reviews of weight-loss treatment generally support emphasizing protein intake during active weight loss. The actual target depends on body weight, age, kidney function, and other conditions, and that is a number to confirm with a clinician rather than to set yourself.
2. Resistance training. The federal physical activity guidelines recommend muscle-strengthening activities at least two days per week for adults. In the weight-loss literature, resistance training is the most consistent intervention associated with preserving lean mass during caloric reduction. Researchers are studying how to apply this specifically to patients on GLP-1 medications, but for now the guidance is straightforward: progressive resistance work, in a form your provider clears, two or more days a week.
A useful comparison is what these strategies look like in practice for GLP-1 patients alongside managing GLP-1 side effects. Both threads, managing the early gastrointestinal effects and protecting lean mass, share the same logic: a structured plan during dose titration is what makes the medication work for you over months, not just weeks.
How a physician-led model addresses this conversation
A prescription alone does not have a protein plan or a resistance-training cadence. A care model does.
A physician-led GLP-1 program treats dose titration as a window, not a formality. During that window, a care coordinator is in touch about nausea, energy, hydration, and the things the patient is actually eating. That is also the window in which the protein and strength-training conversation has the highest chance of becoming a habit, because the patient is making changes anyway. This is a statement about the conversation and the monitoring, not a claim that any program prevents lean-mass change. The medication still does what it does; the program is what makes sure questions get answered before they become reasons to stop.
In practice, that looks like a check-in during the first month, a follow-up at the dose escalation, and a coordinator who reads back to you what the clinician suggested about protein and movement. It is also what separates “got a prescription” from “ran a real plan.” The federal physical activity guidance, the protein literature, and your specific clinician’s read of your situation are the three inputs that should drive the plan, and a real program puts them together.
If you are choosing a provider, ask what the first 90 days of the program actually include and who picks up when something feels off.
What to ask your clinician
A short, specific list to bring to a visit.
- “Given my starting weight, age, and medical history, what protein target should I be aiming for during active weight loss, and how should I spread it across meals?”
- “What resistance-training cadence do you recommend during dose titration, and are there activities I should avoid based on my history?”
- “How will we check in on energy, strength, and any sign of meaningful lean-mass change during the first 90 days?”
- “If I am over 60 (or have a personal history of low muscle mass), what changes for me?”
- “If I plateau, do we re-evaluate the plan before changing the dose?”
These are not abstract questions. They are the questions that turn the science into a plan you can actually run.
For deeper context, our overview of REMEVi’s physician-led GLP-1 program walks through how the visits, coordination, and dose decisions are sequenced, semaglutide vs tirzepatide compared shows where the two molecules differ, and common GLP-1 side effects covers what to expect early. To begin with a clinician, see physician-led weight loss care.
The takeaway
GLP-1 medications produce significant weight loss, and significant weight loss includes some lean-mass change. The SURMOUNT-1 substudy data suggest the proportion is roughly 75% fat and 25% lean, similar to what placebo participants showed and similar to other forms of substantial weight loss. The medication is not the special cause of muscle loss; the weight loss is. What changes the proportion, based on current clinical reviews, is adequate dietary protein and consistent resistance training, ideally inside a program that is actually paying attention.
That is the honest version of the muscle-loss story. Individual results vary, the science continues to develop, and the right protocol for you is one a clinician helps you set.
Your Health. Your Terms. Talk to a real clinician at remevihealth.com.
*This article is for general information and does not constitute medical advice. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a clinician. Compounded semaglutide is a non-FDA-approved preparation prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. It is not a generic version of, and is not the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Compounded preparations have not been clinically studied as finished products. Individual results vary. Consult a licensed provider before starting any weight-loss treatme
